Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models
Maëlle Duffey, Sara E. Zakutansky, Christin Gumpp, Michael J. Delves, Katarzyna A. Sala, Ellie Sherrard-Smith, Jake Baum, Didier Leroy, Matthias Rottmann, Andrew M. Blagborough Communications Medicine
· Springer Nature
· 2026-11-10
· DOI: 10.1038/s43856-026-01977-w
Аннотация
Communications Medicine, Published online: 10 November 2026; doi:10.1038/s43856-026-01977-w Duffey, Zakutansky, et al compare the transmission-blocking activity and drug exposure of primaquine and tafenoquine in two preclinical malaria models. They find that primaquine shows stronger early activity, while tafenoquine maintains activity for longer, supporting further investigation as a transmission-blocking intervention.
Maëlle Duffey, Sara E. Zakutansky, Christin Gumpp, Michael J. Delves, Katarzyna A. Sala, Ellie Sherrard-Smith et al. Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models. // Communications Medicine. – 2026. – DOI: 10.1038/s43856-026-01977-w. – URL: https://www.nature.com/articles/s43856-026-01977-w
Maëlle Duffey, Sara E. Zakutansky, Christin Gumpp, Michael J. Delves, Katarzyna A. Sala, Ellie Sherrard-Smith, Jake Baum, Didier Leroy, Matthias Rottmann, & Andrew M. Blagborough (2026). Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models. Communications Medicine. https://doi.org/10.1038/s43856-026-01977-w
Maëlle Duffey, et al. “Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models.” Communications Medicine, 2026. doi:10.1038/s43856-026-01977-w.
@article{Duffey2026,
title = {Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models},
author = {Duffey, Maëlle and Zakutansky, Sara E. and Gumpp, Christin and Delves, Michael J. and Sala, Katarzyna A. and Sherrard-Smith, Ellie and Baum, Jake and Leroy, Didier and Rottmann, Matthias and Blagborough, Andrew M.},
journal = {Communications Medicine},
year = {2026},
doi = {10.1038/s43856-026-01977-w},
url = {https://www.nature.com/articles/s43856-026-01977-w}
}
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02013-7 The authors identify the mitochondrial RNA methyltransferase, NSUN4 as a potential therapeutic target in intrahepatic cholangiocarcinoma, with...
Communications Medicine, Published online: 19 November 2026; doi:10.1038/s43856-026-02009-3 People with type 2 diabetes can have too much sugar in their blood stream, which can lead to health problems. Metformin is a common medication...
Communications Medicine, Published online: 18 November 2026; doi:10.1038/s43856-026-01992-x ED Summary: O’Connor et al. use a patient-derived organoid co-culture platform to evaluate engineered bacterial therapies for colorectal cancer...
Communications Medicine, Published online: 17 November 2026; doi:10.1038/s43856-026-02012-8 Macrophage Slfn4 attenuates colonic inflammation and tumorigenesis through Rac1-dependent phagocytosis and oxidative burst
Communications Medicine, Published online: 16 November 2026; doi:10.1038/s43856-026-01727-y Ozawa et al. simulated the impact of misinformation in Canada on individuals delaying and refusing vaccination during the COVID-19 pandemic....